ECOG PS
|
2.56 (11. Babjuk M, Oosterlinck W, Sylvester R, Kaasinen E, Böhle A, Palou-Redorta J, et al.: EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update. Eur Urol. 2011; 59: 997-1008.
2. Duncan W, Quilty PM: The results of a series of 963 patients with transitional cell carcinoma of the urinary bladder primarily treated by radical megavoltage X-ray therapy. Radiother Oncol. 1986; 7: 299-310.
3. EAU Guidelines, edition presented at the 25th EAU Annual Congress. 2010.-44. Duchesne GM, Bolger JJ, Griffiths GO, Trevor Roberts J, Graham JD, Hoskin PJ, et al.: A randomized trial of hypofractionated schedules of palliative radiotherapy in the management of bladder carcinoma: resultsof medical research council trial BA09. Int J Radiat Oncol Biol Phys. 2000; 47: 379-88.) |
1.38 (11. Babjuk M, Oosterlinck W, Sylvester R, Kaasinen E, Böhle A, Palou-Redorta J, et al.: EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update. Eur Urol. 2011; 59: 997-1008.-22. Duncan W, Quilty PM: The results of a series of 963 patients with transitional cell carcinoma of the urinary bladder primarily treated by radical megavoltage X-ray therapy. Radiother Oncol. 1986; 7: 299-310.) |
3.37 (33. EAU Guidelines, edition presented at the 25th EAU Annual Congress. 2010.-44. Duchesne GM, Bolger JJ, Griffiths GO, Trevor Roberts J, Graham JD, Hoskin PJ, et al.: A randomized trial of hypofractionated schedules of palliative radiotherapy in the management of bladder carcinoma: resultsof medical research council trial BA09. Int J Radiat Oncol Biol Phys. 2000; 47: 379-88.) |
< 0.0001 |
# Comorbidities
|
2.72 (11. Babjuk M, Oosterlinck W, Sylvester R, Kaasinen E, Böhle A, Palou-Redorta J, et al.: EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update. Eur Urol. 2011; 59: 997-1008.
2. Duncan W, Quilty PM: The results of a series of 963 patients with transitional cell carcinoma of the urinary bladder primarily treated by radical megavoltage X-ray therapy. Radiother Oncol. 1986; 7: 299-310.
3. EAU Guidelines, edition presented at the 25th EAU Annual Congress. 2010.
4. Duchesne GM, Bolger JJ, Griffiths GO, Trevor Roberts J, Graham JD, Hoskin PJ, et al.: A randomized trial of hypofractionated schedules of palliative radiotherapy in the management of bladder carcinoma: resultsof medical research council trial BA09. Int J Radiat Oncol Biol Phys. 2000; 47: 379-88.-55. Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0. May 28, 2009, U.S Department of Health and Human Services; National Institutes of Health; National Cancer Institute.) |
1.92 (11. Babjuk M, Oosterlinck W, Sylvester R, Kaasinen E, Böhle A, Palou-Redorta J, et al.: EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update. Eur Urol. 2011; 59: 997-1008.
2. Duncan W, Quilty PM: The results of a series of 963 patients with transitional cell carcinoma of the urinary bladder primarily treated by radical megavoltage X-ray therapy. Radiother Oncol. 1986; 7: 299-310.
3. EAU Guidelines, edition presented at the 25th EAU Annual Congress. 2010.-44. Duchesne GM, Bolger JJ, Griffiths GO, Trevor Roberts J, Graham JD, Hoskin PJ, et al.: A randomized trial of hypofractionated schedules of palliative radiotherapy in the management of bladder carcinoma: resultsof medical research council trial BA09. Int J Radiat Oncol Biol Phys. 2000; 47: 379-88.) |
3.35(11. Babjuk M, Oosterlinck W, Sylvester R, Kaasinen E, Böhle A, Palou-Redorta J, et al.: EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update. Eur Urol. 2011; 59: 997-1008.
2. Duncan W, Quilty PM: The results of a series of 963 patients with transitional cell carcinoma of the urinary bladder primarily treated by radical megavoltage X-ray therapy. Radiother Oncol. 1986; 7: 299-310.
3. EAU Guidelines, edition presented at the 25th EAU Annual Congress. 2010.
4. Duchesne GM, Bolger JJ, Griffiths GO, Trevor Roberts J, Graham JD, Hoskin PJ, et al.: A randomized trial of hypofractionated schedules of palliative radiotherapy in the management of bladder carcinoma: resultsof medical research council trial BA09. Int J Radiat Oncol Biol Phys. 2000; 47: 379-88.-55. Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0. May 28, 2009, U.S Department of Health and Human Services; National Institutes of Health; National Cancer Institute.) |
0.092 |